Outlook Therapeutics prices $55 million stock and warrant offeringAug 14Financingbevacizumab-vikgOutlook Therapeutics, Inc.
Outlook Therapeutics details LYTENAVA US launch prep in Q3 FY2026 updateAug 14Quarterly updatebevacizumab-vikgOutlook Therapeutics, Inc.
Outlook Therapeutics wins FDA approval for Lytenava in wet AMDJul 24Regulatory decisionbevacizumab-vikgOutlook Therapeutics, Inc.
Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progressJul 23PeoplebevacizumabOutlook Therapeutics, Inc.
Sign inSign in